Renishaw’s Neurolocate 2D Module for Frameless Robotic Neurosurgery Gets CE Mark
GLOUCESTERSHIRE, UK, Oct 2, 2018 – Renishaw is pleased to announce that, its new frameless patient registration module for the neuromate surgical robot, the neurolocate 2D module, has obtained a CE mark. Global engineering company Renishaw will now offer the neurolocate 2D module to hospitals across Europe to help save time and costs by realizing the benefits of intraoperative imaging.
Renishaw neuromate robot with neurolocate module
The new neurolocate 2D module builds on Renishaw’s neurolocate 3D module, which offers the same functionality but requires an intraoperative flat-panel CT system, such as the Medtronic O-Arm. Instead, the new module requires just two X-rays to register patient position against the robot, reducing the need for costly equipment and also reducing radiation exposure.
The neuromate stereotactic robot can be used for a range of functional neurosurgical procedures, including electrode implantation for deep brain stimulation and stereoelectroencephalography (SEEG). It also has applications in biopsy, neuroendoscopy and research.
Renishaw’s neurolocate modules allow the surgeon to accurately determine the position of the patient relative to the neuromate robot. The modules allow the patient to be brought directly into the theatre on the day of surgery, saving time and money for the hospital and reducing procedure time for the patient.
“The neurolocate 2D module is another example of how Renishaw is working to improve the surgical workflow, reduce procedure time and cut operating costs,” said Paul Fielder, Technical Manager at Renishaw’s Neurological Products Division. “The new module can work with pre-existing imaging systems already in a hospital, reducing equipment cost. For the patient, it can mean less time under anesthesia and reduced radiation dosage.”
For more information on Renishaw’s neurological products, visit www.renishaw.com/neuro.
UK-based Renishaw is a world leading engineering technologies company, supplying products used for applications as diverse as jet engine and wind turbine manufacture, through to dentistry and brain surgery. It has over 4,500 employees located in the 36 countries where it has wholly owned subsidiary operations.
For the year ended June 2018, Renishaw recorded sales of £611.5 million of which 95% was due to exports. The company’s largest markets are China, the USA, Germany, and Japan.
Throughout its history, Renishaw has made a significant commitment to research and development, with historically between 13 and 18% of annual sales invested in R&D and engineering. The majority of this R&D and manufacturing of the company’s products is carried out in the UK.
The Company’s success has been recognized with numerous international awards, including eighteen Queen’s Awards recognizing achievements in technology, export, and innovation.
Further information at www.renishaw.com.